null
Med-IQ Express Med-IQ Express

Evaluating the Role of Antinuclear Antibody Testing in Systemic Lupus Erythematosus


This activity was developed by Med-IQ in collaboration with Duke Health.

Med-IQ      Duke Medicine
 

Released:
6/25/19
Expires:
6/24/20

Maximum Credits:

0.25
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Med-IQ Express Med-IQ Express
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
6/25/19

Expires:
6/24/20

Maximum Credits:
0.25
Med-IQ Express Med-IQ Express
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
6/25/19
Expires:
6/24/20


Maximum Credits:
0.25


Overview: This 15-minute accredited CME publication reviews the benefits and limitations of antinuclear antibody (ANA) testing and its utility in systemic lupus erythematosus (SLE). Highlights include an examination of ANA expression in SLE, the role of ANA testing in clinical trials, challenges associated with currently available assays, and novel approaches for ANA testing. In addition, this activity features a short video with expert commentary on ANA testing in SLE.

CME Information:

Faculty
David Stephen Pisetsky, MD, PhD
Professor of Medicine
Professor of Immunology
Department of Medicine
Duke University School of Medicine
Durham, NC
 
Activity Planners
Susan Kuhn, MHSc
Manager, Educational Strategy and Content
Med-IQ
Baltimore, MD
 
Laura Rafferty, ELS
Managing Editor
Med-IQ
Baltimore, MD
 
Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI
 
Writer
Aimee Spevak, MPH
MedLitera
Vashon, WA
 
Learning Objectives
Upon completion, participants should be able to:

  • Describe the role of ANAs as biomarkers for SLE, patient assessment tools, and clinical trial inclusion criteria
  • Evaluate the benefits and limitations of ANA assays in SLE patient care

Target Audience
This activity is intended for rheumatologists and clinicians involved in delivering care to patients with systemic lupus erythematosus.
 
Statement of Need
ANAs commonly occur in patients with a variety of autoimmune and inflammatory diseases and are frequently used to screen patients for diseases such as SLE; however, ANAs are found in as many as 30% of otherwise healthy individuals, limiting the utility of ANA testing for screening. Although ANA expression has long been considered an important aspect of SLE diagnosis, studies reveal that as many as 20% to 30% of patients with established SLE may be ANA negative. This surprising finding emerged from clinical studies exploring a new therapy for SLE. Thus, SLE patients being considered for a clinical trial must be ANA positive, and drugs for SLE may receive approval specifically for “active, autoantibody-positive disease.” Furthermore, in an effort to improve the diagnosis and care of patients with SLE, new criteria for disease classification now include ANA positivity as a designated entry criterion. However, considerable variability exists in the laboratory assays used for ANA detection, further complicating their utility. Thus, clinicians require a better understanding of the complex issues surrounding ANA testing and its use in SLE.

Collaboration Statement
This activity was developed by Med-IQ in collaboration with Duke Health.
 
Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Medium/Method of Participation
This CME activity consists of a 0.25-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: June 25, 2019
Expiration Date: June 24, 2020
Estimated Time to Complete This Activity: 15 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
David Stephen Pisetsky, MD, PhD
Consulting fees/advisory boards: Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc.

Susan Kuhn, MHSc
Spouse Ownership interest (stocks/stock options – excluding mutual funds):  Illumina, Johnson & Johnson, Viking Therapeutics                              
 
The writer, peer reviewers, and other activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
 
Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
 
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
 
Copyright
© 2019 Med-IQ, Inc. and Duke University Health System

 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.